Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient [0.03%]
优化铂敏感复发性卵巢癌患者的治疗
Nicoletta Colombo
Nicoletta Colombo
The choice of second-line chemotherapy in patients with recurrent ovarian cancer (ROC) is complex, with several factors to be considered, the most important of which is the length of the platinum-free treatment interval (PFI). Recently ROC ...
Hani Gabra
Hani Gabra
Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of death from gynaecological cancer, and is the 4th most common cause of cancer death among UK women. Similar to the majority of other cancers, r...
Beyond treatment - Psychosocial and behavioural issues in cancer survivorship research and practice [0.03%]
超越治疗——癌症幸存者心理社会及行为问题的研究与实践
Neil K Aaronson,Vittorio Mattioli,Ollie Minton et al.
Neil K Aaronson et al.
The population of cancer survivors has grown steadily over the past several decades. Surviving cancer, however, is not synonymous with a life free of problems related to the disease and its treatment. In this paper we provide a brief overvi...
Leslie R Schover,Marleen van der Kaaij,Eleonora van Dorst et al.
Leslie R Schover et al.
Sexual dysfunction is a common consequence of cancer treatment, affecting at least half of men and women treated for pelvic malignancies and over a quarter of people with other types of cancer. Problems are usually linked to damage to nerve...
Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions [0.03%]
癌症患者的认知功能监测和优化：现状与未来方向
S B Schagen,M Klein,J C Reijneveld et al.
S B Schagen et al.
The potentially detrimental effects of cancer and related treatments on cognitive functioning are emerging as a key focus of cancer survivorship research. Many patients with central nervous system (CNS) or non-CNS tumours develop cognitive ...
Berthe M P Aleman,Elizabeth C Moser,Janine Nuver et al.
Berthe M P Aleman et al.
Improvements in treatment and earlier diagnosis have both contributed to increased survival for many cancer patients. Unfortunately, many treatments carry a risk of late effects including cardiovascular diseases (CVDs), possibly leading to ...
Current knowledge and future research directions in treatment-related second primary malignancies [0.03%]
治疗相关继发性恶性肿瘤的当前认识和未来研究方向
Lindsay M Morton,Anthony J Swerdlow,Michael Schaapveld et al.
Lindsay M Morton et al.
Currently, 17-19% of all new primary malignancies occur in survivors of cancer, causing substantial morbidity and mortality. Research has shown that cancer treatments are important contributors to second malignant neoplasm (SMN) risk. In th...
Cancer survivorship: A positive side-effect of more successful cancer treatment [0.03%]
癌症幸存：更成功癌症治疗的积极副作用
Elizabeth Charlotte Moser,Françoise Meunier
Elizabeth Charlotte Moser
Over the past decades, early diagnosis, new drugs and more personalised multi-modality treatment have led to impressive increases in survival rates of patients with cancer. This success in treating cancer has resulted in a large and rapidly...
Håkan Mellstedt
Håkan Mellstedt
Biosimilar agents are approximate copies of branded biologic therapies. Since the first biosimilar was authorized in the European Union in 2006, fifteen additional agents have been approved by the European Medicines Agency, including two bi...